Skip to main content - [accesskey + 1] Skip to navigation - [accesskey + 2] Skip to sidebar - [accesskey + 3]

Research Drugs

The Drug Information System "AMIce" contains information about pharmaceutical substances and medicinal products marketed nationally and internationally (e.g. application, adverse effects and interactions). Health care professionals (except physicians) and medical journalists can use the ABDA database.

AMIce

AMIce contains data for different user groups. "AMIce-Public Part can be accessed publicly and free of charge.

ABDA

The ABDA database contains of comprehensive data concerning medicinal drugs and substances as well as drug-related information.

Prices and Conditions

The BfArM offers weekly or annual flat fees for research in the databases.

PLEASE NOTE

Due to technical maintenance work our web applications will not be accessible on Saturday, 17 April 2021 between 8:00 and approx. 18:00.
We apologize for any inconveniences caused.

PLEASE NOTE

On August 31, 2020, the previous drug information system AMIS was replaced by AMIce. With the changeover, the search interface was designed to be clearer and more accessible.

Existing login data can be used as usual for all user groups.

The database is only available in German language.

Restrictions and Contact (in German language)

AMIce DATABASE SEARCH

limited data volume, usable free of charge

full data volume, usable via flat fee

ABDA DATABASE SEARCH

RESEARCH FLAT FEES

Buy Flat Fees

Forgot Password?

PRICE INFO

An overview of the different flat fees can be found under:

Price Info

FREQUENTLY ASKED QUESTIONS AND GLOSSARY

You find answers to frequently asked questions on our FAQ page (in German).

FAQ Drugs

CONTACT DRUGS

Phone: +49 228 99307-4944

Contact Form

This website uses session cookies to ensure certain functionalities such as downloads or login to closed areas. In order to optimize the website, we use the analysis tool Matomo. Our Matomo installation works without tracking cookies. You will find more detailed information and the possibilities to object to the use of Matomo in our data privacy declaration.